Table 4 NLR and PLR of Hsp90-beta serum level in lung cancer patients and control individuals
Interval | Positive | Negative | Likelihood ratio | 95% CI |
|---|---|---|---|---|
NLR and PLR of serum Hsp90-beta for differentiating lung cancer patients from control individuals | ||||
0.6–0.8 | 8 | 21 | 0.178 | 0.0848 to 0.374 |
0.8–1.0 | 0 | 16 | 0.000 | 0.000 to 0.239 |
1.0–1.2 | 9 | 5 | 0.841 | 0.297 to 2.381 |
1.2–1.4 | 49 | 1 | 22.897 | 3.254 to 161.134 |
1.4–1.6 | 41 | 1 | 19.159 | 2.712 to 135.355 |
1.6–1.8 | 0 | 6 | 0.000 | 0.000 to 0.684 |
Total | 107 | 50 | ||
NLR and PLR of MPE Hsp90-beta for differentiating lung cancer patients from control individuals | ||||
1.0–1.2 | 3 | 20 | 0.0584 | 0.0185 to 0.185 |
1.2–1.4 | 4 | 17 | 0.0984 | 0.0353 to 0.274 |
1.4–1.6 | 8 | 2 | 17.33 | 6.4 to 26.78 |
1.6–1.8 | 15 | 4 | 25.87 | 3.19 to 36.98 |
1.8–2.0 | 71 | 2 | 21.963 | 5.638 to 85.550 |
2.0–2.2 | 4 | 5 | 0.374 | 0.105 to 1.333 |
2.2–2.4 | 1 | 0 | ∞ | 0.0319 to ∞ |
Total | 107 | 50 | ||